1. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function
- Author
-
David Price, Fiyaz Mohammed, Benjamin E. Willcox, Louisa Green, Emma C. Morris, David Stirling, Rogier M. Reijmers, Theresa Stauss, Hans J. Stauss, Angelika Holler, Benjamin M. Chain, Sharyn Thomas, Katherine K. Matthews, Alan Kennedy, Mirjam H.M. Heemskerk, Annemarie Woolston, and David T. Jones
- Subjects
Antigens, Differentiation, T-Lymphocyte ,Male ,Models, Molecular ,0301 basic medicine ,Adoptive cell transfer ,T-Lymphocytes ,medicine.medical_treatment ,Translational immunology ,Gene Expression ,General Physics and Astronomy ,Cancer immunotherapy ,Mice, SCID ,Lymphocyte Activation ,Protein Engineering ,Mice ,0302 clinical medicine ,Mice, Inbred NOD ,T-cell receptor ,lcsh:Science ,Cell Engineering ,Multidisciplinary ,Effector ,Chemistry ,food and beverages ,hemic and immune systems ,Cell biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cytokines ,Science ,T cell ,Receptors, Antigen, T-Cell ,chemical and pharmacologic phenomena ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Protein Domains ,Antigen ,Antigens, CD ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Lectins, C-Type ,Antigens ,Cell Proliferation ,Cell growth ,fungi ,Genetic Therapy ,General Chemistry ,Genes, T-Cell Receptor ,030104 developmental biology ,Cell culture ,lcsh:Q ,Protein design - Abstract
TCR-gene-transfer is an efficient strategy to produce therapeutic T cells of defined antigen specificity. However, there are substantial variations in the cell surface expression levels of human TCRs, which can impair the function of engineered T cells. Here we demonstrate that substitutions of 3 amino acid residues in the framework of the TCR variable domains consistently increase the expression of human TCRs on the surface of engineered T cells.The modified TCRs mediate enhanced T cell proliferation, cytokine production and cytotoxicity, while reducing the peptide concentration required for triggering effector function up to 3000-fold. Adoptive transfer experiments in mice show that modified TCRs control tumor growth more efficiently than wild-type TCRs. Our data indicate that simple variable domain modifications at a distance from the antigen-binding loops lead to increased TCR expression and improved effector function. This finding provides a generic platform to optimize the efficacy of TCR gene therapy in humans., Increasing TCR cell surface expression can potentiate T cell responses to low-concentrations of antigen. Here the authors identify aminoacids in human TCR variable domains that impact its surface expression, and demonstrate how editing these residues can improve T cell activation and effector function without altering antigen specificity.
- Published
- 2019